Drugs / Odetiglucan
Odetiglucan
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05484011 | Dec 2022 → Mar 2024 | pancreatic adenocarcinoma | HiberCell, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07199764 | Nov 2025 → Oct 2027 expected | pancreatic ductal adenocarcinoma | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT07082439 | Sep 2025 → Sep 2027 expected | colorectal adenocarcinoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Odetiglucan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07082439 ↗ |
| Known as | Odetiglucane | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095284 ↗ |
| Known as | Odetiglucano | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095284 ↗ |
| Modality | Other / unclassified | “Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain.” NCT05484011 ↗ |
| Route | Intravenous | “Dose Level 1: Odetiglucan 4 mg/kg IV plus CDX-1140 1.5 mg/kg” NCT05484011 ↗ |